Experimental rabies vaccines for humans

References

• Jackson AC. Rabies. Neurolog. Clin.26(3), 717–726 (2008).
   PubMed Web of Science ®Google Scholar
• WHO. Rabies and Envenomings, a Neglected Public Health Issue. Report of a Consultative Meeting. WHO, Geneva, Switzerland (2007).
   Google Scholar
• Blanton JD, Palmer D, Christian KA, Rupprecht CE. Rabies surveillance in the United States during 2007. J. Am. Vet. Med. Assoc.233(6), 884–897 (2008).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis.47(3), 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Turner GS. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine. J. Gen. Virol.40, 595–604 (1978).
   Google Scholar
• Perry LL, Lodmell DL. Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus. J. Virol.65(7), 3429–3434 (1991).
   PubMed Web of Science ®Google Scholar
• Brinkman DM, Jol-van der Zijde CM, ten Dam MM et al. Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man. J. Clin. Immunol.23(6), 528–538 (2003).
   Google Scholar
• Perrin P, Joffret ML, Zanetti C et al. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees. Vaccine9(8), 549–558 (1991).
   Google Scholar
• Uytdehaag FG, Osterhaus AD, Loggen HG et al. Induction of antigen-specific antibody response in human peripheral blood lymphocytes in vitro by a dog kidney cell vaccine against rabies virus (DKCV). J. Immunol. (Baltimore)131(3), 1234–1239 (1983).
   Google Scholar
• Moore SM, Wilkerson MJ, Davis RD, Wyatt CR, Briggs DJ. Detection of cellular immunity to rabies antigens in human vaccinees. J. Clin. Immunol.26(6), 533–545 (2006).
   Google Scholar
• Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood114(24), 4998–5002 (2009).
   PubMedGoogle Scholar
• Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine23(11), 1414–1425 (2005).
   PubMed Web of Science ®Google Scholar
• Otvos L Jr, Hollosi M, Perczel A, Dietzschold B, Fasman GD. Phosphorylation loops in synthetic peptides of the human neurofilament protein middle-sized subunit. J. Protein Chem.7(4), 365–376 (1988).
   Google Scholar
• Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination. Vaccine28(23), 3896–3901 (2010).
   PubMed Web of Science ®Google Scholar
• WHO. WHO Position Paper on rabies vaccines. Weekly Epidemiol. Record82(49/50), 425–436 (2007).
   PubMedGoogle Scholar
• Rupprecht CE, Briggs D, Brown CM et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Weekly Rep.59(RR-2), 1–9 (2010).
   PubMedGoogle Scholar
• Warrell MJ, Suntharasamai P, Nicholson KG et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet1(8382), 874–876 (1984).
   PubMed Web of Science ®Google Scholar
• Suntharasamai P, Warrell MJ, Viravan C et al. Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis. Epidemiol. Infect.99(3), 755–765 (1987).
   PubMed Web of Science ®Google Scholar
• Lang J, Hoa DQ, Gioi NV et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans. Royal Soc. Trop. Med. Hygiene93(2), 208–213 (1999).
   PubMed Web of Science ®Google Scholar
• Warrell MJ, Riddell A, Yu LM et al. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Neglect. Trop. Dis.2(4), e224 (2008).
   PubMed Web of Science ®Google Scholar
• Strady C, Andreoletti L, Baumard S et al. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans. Royal Soc. Trop. Med. Hygiene103(11), 1159–1164 (2009).
   PubMed Web of Science ®Google Scholar
• Cenna J, Tan GS, Papaneri AB et al. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine26(50), 6405–6414 (2008).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – ‘the long and winding road’. Drug Discov. Today14(11–12), 541–551 (2009).
   PubMed Web of Science ®Google Scholar
• Ertl HC. Novel vaccines to human rabies. PLoS Neglect. Trop. Dis. (Electronic Resource)3(9), e515 (2009).
   Google Scholar
• Wang X, Bao M, Wan M et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine26(15), 1893–1901 (2008).
   Google Scholar
• Ramya R, Verma PC, Chaturvedi VK et al. Poly(lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus. Vaccine27(15), 2138–2143 (2009).
   Google Scholar
• Chulasugandha P, Khawplod P, Havanond P, Wilde H. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine24(9), 1478–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Kamoltham T, Thinyounyong W, Phongchamnaphai P et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J. Pediatrics151(2), 173–177 (2007).
   PubMed Web of Science ®Google Scholar
• Lang J, Duong GH, Nguyen VG et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet349(9066), 1663–1665 (1997).
   PubMedGoogle Scholar
• Lang J, Feroldi E, Vien NC. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam. J. Trop. Pediatrics55(1), 26–31 (2009).
   PubMedGoogle Scholar
• Lumbiganon P, Chaiprasithikul P, Sookpranee T, Paholpak S, Wasi C. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pacif. J. Allergy Immunol.7(2), 99–101 (1989).
   PubMed Web of Science ®Google Scholar
• Pengsaa K, Limkittikul K, Sabchareon A et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr. Infect. Dis. J.28(4), 335–337 (2009).
   PubMed Web of Science ®Google Scholar
• Shanbag P, Shah N, Kulkarni M et al. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). Hum. Vaccines4(5), 365–369 (2008).
   PubMed Web of Science ®Google Scholar
• Dodet B, Asian Rabies Expert B. An important date in rabies history. Vaccine25(52), 8647–8650 (2007).
   Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today8(20), 934–943 (2003).
   PubMed Web of Science ®Google Scholar
• Weyer J, Rupprecht CE, Nel LH. Poxvirus-vectored vaccines for rabies – a review. Vaccine27(51), 7198–7201 (2009).
   PubMed Web of Science ®Google Scholar
• Ertl HC. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin. Biol. Ther.3(4), 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol.8(1), 51–61 (2010).
   PubMed Web of Science ®Google Scholar
• Wunner WH. Rabies Virus. Jackson AC, Wunner WH (Eds). Elsevier Science, CA, USA (2007).
   Google Scholar
• Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J.13(18), 4195–4203 (1994).
   PubMed Web of Science ®Google Scholar
• McGettigan JP, Pomerantz RJ, Siler CA et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol.77(1), 237–244 (2003).
   PubMed Web of Science ®Google Scholar
• Faul EJ, Aye PP, Papaneri AB et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine28(2), 299–308 (2009).
   PubMedGoogle Scholar
• McKenna PM, Koser ML, Carlson KR et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis.195(7), 980–988 (2007).
   PubMedGoogle Scholar
• Dietzschold B, Fields BN. Rhabdoviruses. In: Fields Virology. Lippincott-Raven Publishers, PA, USA, 1137–1152 (1996).
   Google Scholar
• Rose JK, Schubert M. Rhabdovirus Genomes and Their Products. Wagner RR (Ed.). Plenum Publishing Corp., NY, USA (1987).
   Google Scholar
• Brzozka K, Finke S, Conzelmann KK. Identification of the rabies virus a/b interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol.7673–7681 (2005).
   Google Scholar
• Brzozka K, Finke S, Conzelmann KK. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol.80(6), 2675–2683 (2006).
   PubMed Web of Science ®Google Scholar
• Shoji Y, Inoue S, Nakamichi K et al. Generation and characterization of P gene-deficient rabies virus. Virology318(1), 295–305; 295–305 (2004).
   Google Scholar
• Faber M, Pulmanausahakul R, Hodawadekar SS et al. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol.76(7), 3374–3381 (2002).
   PubMed Web of Science ®Google Scholar
• Megret F, Prehaud C, Lafage M et al. Immunopotentiation of the antibody response against influenza HA with apoptotic bodies generated by rabies virus G-ERA protein-driven apoptosis. Vaccine16(23), 5342–5350 (2005).
   Google Scholar
• Mebatsion T, Weiland F, Conzelmann KK. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol.73(1), 242–250 (1999).
   PubMed Web of Science ®Google Scholar
• Cenna J, Hunter M, Tan GS et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis.200(8), 1251–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Ito N, Sugiyama M, Yamada K et al. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol.49(11), 971–979 (2005).
   Google Scholar
• Shearer MH, Dark RD, Chodosh J, Kennedy RC. Comparison and characterization of immunoglobulin G subclasses among primate species. Clin. Diag. Lab. Immunol.6(6), 953–958 (1999).
   PubMedGoogle Scholar
• Burton DR. Antibodies, viruses and vaccines. Nat. Rev. Immunol.2(9), 706–713 (2002).
   PubMed Web of Science ®Google Scholar
• Phares TW, Kean RB, Mikheeva T, Hooper DC. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. (Baltimore)176(12), 7666–7675 (2006).
   PubMedGoogle Scholar
• Mebatsion T, Konig M, Conzelmann KK. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell84(6), 941–951 (1996).
   PubMed Web of Science ®Google Scholar
• Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol.84(6), 2820–2831 (2010).
   PubMedGoogle Scholar
• Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol.3(6), 493–502 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper DC, Phares TW, Fabis MJ, Roy A. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Neglect. Trop. Dis. (Electronic Resource)3(10), e535 (2009).
   PubMed Web of Science ®Google Scholar
• Baer GM, Shaddock JH, Williams LW. Prolonging morbidity in rabid dogs by intrathecal injection of attenuated rabies vaccine. Infect. Immun.12(1), 98–103 (1975).
   Google Scholar
• Faber M, Li J, Kean RB et al. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA106(27), 11300–11305 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao L, Toriumi H, Kuang Y, Chen H, Fu ZF. The roles of chemokines in rabies virus infection: overexpression may not always be beneficial. J. Virol.83(22), 11808–11818 (2009).
   PubMed Web of Science ®Google Scholar
• Belotto A, Leanes LF, Schneider MC, Tamayo H, Correa E. Overview of rabies in the Americas. Virus Res.111(1), 5–12 (2005).
   PubMed Web of Science ®Google Scholar
• Lembo T, Hampson K, Kaare MT et al. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl. Trop. Dis.4(2), e626 (2010).
   PubMed Web of Science ®Google Scholar
• Schneider MC, Belotto A, Ade MP et al. Current status of human rabies transmitted by dogs in Latin America. Cad Saude Publica23(9), 2049–2063 (2007).
   PubMed Web of Science ®Google Scholar
• Baer GM. The history of rabies. In: Rabies. Jackson AC, Wunner WH (Eds). Elsevier Science CA, USA, 11–19 (2007).
   Google Scholar